- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Improved Detection of Metastasized Prostate Cancer with a New Tracer
A study conducted at the Johns Hopkins University demonstrates improved detection of prostate cancer metastasis following the injection of 18F-DCFBC, which binds PSMA.
A new radiotracing agent injected before PET/CT might improve the detection of metastasized prostate cancer, compared with conventional imaging, in patients with castration-resistant disease, according to preliminary results from a new study.
The agent, known as 18F-DCFBC, binds to prostate-specific membrane antigen (PSMA), a protein that is "highly expressed in prostate cancer, allowing for optimal signal detection," senior author Steve Cho, MD, PhD, from Johns Hopkins University School of Medicine in Baltimore, Maryland, told Medscape Medical News.
His group previously showed, in a first-in-human trial, that the tracer could detect sites of metastatic prostate cancer (J Nucl Med. 2012;53:1883-1891).
Original report: http://bit.ly/1s5rW6f
Source: Medscape
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
